Development of a virtual Rheumatoid Arthritis synovial fibroblast for large-scale dynamic analysis and efficient drug-target identification

Rheumatoid arthritis (RA) is a complex, systemic autoimmune disease that primarily affects the lining of the synovial joints and involves an intricate interplay among genotype and environmental triggers. Early RA starts with the infiltration of the synovial compartment by leukocytes. Then, the synovial fluid is inundated with pro-inflammatory mediators inducing an inflammatory cascade characterised by fibroblast-like synoviocytes (FLS) interactions with cells of the innate and adaptive immune system. Cytokines are key mediators, whereas drugs inhibiting these cytokines lead to RA therapies. Unfortunately, 40% of patients fail to respond to therapy.

Recently, many studies have shown that RA FLS activation and the subsequent joint damage they perpetuate are associated with an altered metabolism that may be therapeutically targetable.Thus, RA FLS-directed therapies could become a complementary approach to immune-directed therapies.

Who is this course for?

This webinar is part ofPerMedCoEwebinar series and is open for anyone interested inPerMedCoE products and developments, as well as for researchers in the life sciences, bioinformaticians and life sciences software developers.

The goal of PerMedCoE is to provide an efficient and sustainable entry point to the HPC/Exascale-upgraded methodology to translate omics analyses into actionable models of cellular functions of medical relevance.

Outcomes

By the end of this webinar, you will be able to:

• Describe how a virtual RA FLS model can be used to describe clinical intervention points
• Describe how computational methods can simulate large-scale biological models